story of the week
NECTIN4 Amplification as a Genomic Biomarker to Predict Enfortumab Vedotin Response in Metastatic Urothelial Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer
J. Clin. Oncol 2024 Apr 24;[EPub Ahead of Print], N Klümper, NK Tran, S Zschäbitz, O Hahn, T Büttner, F Roghmann, C Bolenz, F Zengerling, C Schwab, D Nagy, M Toma, G Kristiansen, H Heers, P Ivanyi, G Niegisch, CM Grunewald, C Darr, A Farid, K Schlack, M Abbas, C Aydogdu, J Casuscelli, T Mokry, M Mayr, D Niedersüß-Beke, S Rausch, D Dietrich, J Saal, J Ellinger, M Ritter, A Alajati, C Kuppe, J Meeks, FE Vera Badillo, JA Nakauma-González, J Boormans, K Junker, A Hartmann, V Grünwald, M Hölzel, M EcksteinFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.